Surefire Infusion System Found Safe and Effective for Delivery of 90Y in Treating Inoperable Liver Cancer
Case reports published in the Journal of Cardiovascular and Interventional Radiology found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels, a significant advance that may enable doctors to safely extend liver cancer treatment to patients who were previously deemed untreatable.
None of the three patients, including one who otherwise could not have been treated, suffered complications as a result of the minimally invasive procedure. All were discharged the following day.
"With the protection from reflux afforded by Surefire's novel, expandable, funnel-shaped tip we performed successful yttrium-90 radioembolization without coiling," said Prof. Dr. Maurice van den Bosch, Interventional Radiologist, University Medical Center Utrecht, The Netherlands. "Positron emission tomography-computed tomography (PET-CT) confirmed adequate, efficient biodistribution of the microspheres in targeted liver segments only."
In recent years, Interventional Oncology has emerged as a pillar of modern cancer care. In numerous clinical studies, improved patient outcomes have been achieved with embolization therapy and systemic chemotherapy compared to systemic chemotherapy alone.
"We are gratified that our advanced technology enables a broader population of patients to be treated, including those who otherwise may not have received treatment," said Surefire Medical CEO Jim Chomas. "These case studies add to the rapidly growing body of clinical evidence indicating that the Surefire Infusion System safely, efficiently and precisely delivers therapy. It may contribute not only to enhanced treatment effectiveness, but also to the palliation of cancers to improve quality of life."
About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop a new class of infusion systems for the interventional radiology and interventional oncology markets. Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. For more information, please visit www.surefiremedical.com.